Therefore, as ACSL4 regulates ERα expression and the mTOR pathway, our results provide evidence that ACSL4 could be also an interesting target, in combination with 4-OHTAM, to restore tumor hormone dependence in tumors with poor prognosis and low survival rates. The gene discussed is ESR1; the disease is neoplasm.